Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Clarus leads £21mm Series A in Heptares Therapeutics

Executive Summary

GPCR drug discovery start-up Heptares Therapeutics has raised £21mm ($30mm) in its Series A financing led by Clarus Ventures, which was joined by fellow new backer Novartis Option Fund and returning shareholder MVM Life Science Partners. Each investor put £7mm into the company, and Clarus and Novartis Option Fund contributed new board members.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies